Description
HGH Fragment 176-191 | Selective Lipolytic Peptide — Research Grade
HGH Fragment 176-191 corresponds to residues 176-191 of human growth hormone and contains the region responsible for GH lipolytic activity. A disulfide bond between Cys182 and Cys189 maintains the bioactive conformation. It has received FDA GRAS status and has been evaluated in Phase II obesity trials.
Mechanism of Action
- Beta-3 adrenergic activation — stimulates lipolysis in adipocytes via beta-3-AR pathway, not GH receptor
- ACC inhibition — reduces de novo lipogenesis by inhibiting acetyl-CoA carboxylase
- No GHR binding — does not activate the growth hormone receptor or alter IGF-1 or insulin levels
Research Areas
Studied in fat metabolism, obesity (Phase II RCT data available), osteoarthritis (Phase IIa), and as a selective lipolytic tool separate from full GH bioactivity research.
For Research Use Only. Rainbow Peptide supplies Fragment 176-191 exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. S. Bloom –
GH Fragment 176-191 for our adipocyte lipolysis and fat-loss mechanism research. Purity confirmed at 98.9% HPLC. Beta-3 adrenergic receptor activation response in our fat cell model matched published data. Excellent COA.
T. Magnusson –
Consistent quality across three lots of Fragment 176-191. Our lipid metabolism model relies on tight lot consistency. COA detailed and includes mass spec. Fast shipping, temperature-controlled delivery.
N. Boateng –
GH Fragment 176-191 dissolved easily in saline. Purity >98%. COA includes full HPLC trace. Adipocyte model showed expected lipolytic activity. Good quality at a reasonable price for research use.